Second Booster Dose for Targeted Populations

July 7, 2022

On March 29, 2022, the U.S. Food and Drug Administration (FDA) made changes to the Emergency Use Authorization (EUA) of the Pfizer and Moderna COVID-19 vaccines to allow for a second booster dose of the vaccine. In addition, the FDA authorized a manufacturing change for the Moderna COVID-19 vaccine, allowing for a booster formulation to be available in the marketplace.

Effective for dates of service on or after March 29, 2022, the FDA amended the EUA for both the Pfizer-BioNTech and Moderna COVID-19 vaccines to allow for use of a second booster dose to be administered to the following groups at least four months after the initial booster dose:

Pfizer-BioNTech COVID-19 Vaccine:

- Individuals 12 years of age or older with certain kinds of immunocompromise. This includes individuals who have undergone solid organ transplantation or who are living with conditions that are considered to have an equivalent level of immunocompromise.
- Individuals 50 years of age and older.

Moderna COVID-19 Vaccine:

- Individuals 18 years of age or older with certain kinds of immunocompromise. This includes individuals who have undergone solid organ transplantation or who are living with conditions that are considered to have an equivalent level of immunocompromise.
- Individuals 50 years of age and older.

Additionally, effective for dates of service on or after March 29, 2022, the FDA authorized a booster dose formulation (50 mcg/0.5 ml) for the Moderna COVID-19 vaccine. The Moderna COVID-19 vaccine booster formulation is authorized for individuals 18 years of age and older and is only authorized for the first or second booster dose (not authorized for the primary vaccination series). Either of the following National Drug Codes must be utilized when billing for the 50 mcg/0.5 ml formulation:

- 80777027505
- 80777027599